Brind.
  1. BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.
  2. Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.

Novo Nordisk alleged Hims & Hers failed to adhere to law.

9 reports, 4 independent Updated Aug 13
Gone quiet Reached 4 outlets in its first 24 hours
Reports
9
Developments
6
Repetition
22%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

Novo Nordisk alleged Hims & Hers failed to adhere to law.

Who's involved

What this event is mainly about
Hims & Hers HealthNovo Nordisk

How it developed

Newest first. Tap a step to see who reported it.
  1. Novo Nordisk offered Wegovy via Hims & Hers platform; company also faces legal pressure.1 source
  2. Novo Nordisk ramps up lawsuits against Hims & Hers over cheaper Wegovy copies.1 source
  3. Companies involved are dealing with selling knockoffs of weight loss drug formulas and patented drugs after shortages ended.1 source
  4. Novo Nordisk terminated its partnership with Hims & Hers Health.2 sources
  5. Novo Nordisk alleged Hims & Hers failed to adhere to law.
  6. Novo Nordisk shifts view of Hims & Hers from partner to competitor.

Keep exploring

Part of

Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.

Also in this story

All 6 developments

Within BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • StockStoryWhy Hims & Hers Health (HIMS) Shares Are Trading Lower Today Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock s
  • ReutersAs Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims? By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmaci
  • Motley FoolHims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analy
  • Motley FoolWhy Hims & Hers Stock Sank This Week Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical compa
  • ZacksBull of the Day: Hims & Hers Health (HIMS) Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcar
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet